Know Cancer

or
forgot password
  • cancer clinical trials in asheboro, NC

  • Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Breast Cancer
    Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Breast Cancer
    Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Endometrial Cancer
    Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
    Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    Randolph Hospital
    Asheboro, North Carolina 27203
    Brain and Central Nervous System Tumors
    Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Adenocarcinoma of the Colon, Stage II Colon Cancer
    Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    Randolph Hospital
    Asheboro, North Carolina 27203
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
    Randolph Hospital
    Asheboro, North Carolina 27203
    Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
    Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
    Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Randolph Hospital
    Asheboro, North Carolina 27203
    Lymphoma
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
    Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer, Stage IVB Cervical Cancer
    Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
    S9925: Collecting and Storing Samples From Patients With Lung Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Lung Cancer
    Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Stage IV Prostate Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
    Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
    Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Chemotherapeutic Agent Toxicity, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Pain, Peripheral Neuropathy, Primary Peritoneal Cavity Cancer
    Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
    Randolph Hospital
    Asheboro, North Carolina 27203
    Colorectal Cancer, Precancerous Condition
    Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
    Randolph Hospital
    Asheboro, North Carolina 27203
    Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
    Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Breast Cancer
    Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
    Randolph Hospital
    Asheboro, North Carolina 27203
    Kidney Cancer
    Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
    Randolph Hospital
    Asheboro, North Carolina 27203
    Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma
    Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
    Randolph Hospital
    Asheboro, North Carolina 27203
    Diarrhea, Gastrointestinal Complications, Unspecified Adult Solid Tumor, Protocol Specific
    Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
    Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
    Randolph Hospital
    Asheboro, North Carolina 27203
    Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma
    Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
    Randolph Cancer Center
    Asheboro, North Carolina 27203
    Multiple Myeloma
    S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
    Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
    Randolph Hospital
    Asheboro, North Carolina 27203
    Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Secondary Myelodysplastic Syndromes
    High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
    Randolph Hospital
    Asheboro, North Carolina 27203
    Melanoma (Skin)
    Combination Chemotherapy in Treating Patients With Bladder Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Bladder Cancer
    Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Head and Neck Cancer
    S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Pancreatic Cancer
    Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
    Asheboro Urology
    Asheboro, North Carolina 27203
    Prostate Cancer, Osteoporosis, Fractures
    A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients
    Duramed Investigational Site
    Asheboro, North Carolina 27203
    Prostate Cancer
    S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT
    Randolph Hospital
    Asheboro, North Carolina 27203
    Prostate Cancer
    Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
    Randolph Hospital
    Asheboro, North Carolina 27203
    Lung Cancer